CELSR3 and prostate adenocarcinoma: To further investigate the prognostic value of CELSR3 in PCa, we performed a univariate and multivariate Cox proportional hazard regression to validate the clinical prognostic value of CELSR3 in the PRAD dataset (Table 3).